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Background: Inhibition of prolyl hydroxylases (PHDs) leads to the induction of a transcriptional program that, in
the gut, promotes intestinal epithelial cell survival. PHD inhibitors have recently been suggested as a promising
alternative treatment for inflammatory bowel disease (IBD). In this study, we explored the colonic mucosal
expression of the different PHD-isoforms (PHD1, 2 and 3) in order to identify the key isoform(s) involved in the
pathogenesis of IBD.
Methods: The mRNA expression of inflammatory cytokines (IL-8 and TNF-α), an apoptosis marker (caspase 3) and
PHD1, 2 and 3 was analysed in biopsies of IBD patients (UC and CD), patients with infectious colitis and healthy
controls using qRT-PCR. PHD protein levels were evaluated using western blot. Cellular localization of PHD 1, 2 and
3 was determined by immunohistochemistry.
Results: PHD1 was significantly up-regulated in IBD patients, both at the mRNA (UC: p < 0.0001 and CD: p < 0.05)
and at the protein level (UC: p < 0.05 and CD: p < 0.05), and showed a very good correlation with the expression of
the inflammatory cytokines IL-8 and TNF-α and the apoptosis marker caspase 3. Colonic mucosal PHD2 mRNA and
protein expressions were not altered in IBD. PHD3 expression was increased in inflamed biopsies from UC patients
(p < 0.0001), but only at the mRNA level. PHD1 and PHD2 expression was found both in the colonic lamina propria
and the epithelium while PHD3 was mainly located in the endothelium of blood vessels.
Conclusions: In this exploratory expression analysis, PHD1 comes forward as the primary therapeutic target for UC
and, to a lesser extent, for (colonic) CD.
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Background
Prolyl hydroxylase domain-containing proteins (PHDs) are
oxygen sensing enzymes that, under normoxic conditions,
hydroxylate the hypoxia-inducible factor 1 alpha subunit
(HIF-1α), leading to its proteasomal degradation. During
hypoxia, the PHDs are inhibited, leading to the formation
of the active transcription factor HIF-1, which induces
the expression of several cell survival genes (i.e. the* Correspondence: pieter.hindryckx@ugent.be
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distribution, and reproduction in any mediumhypoxic adaptive response) [1]. Several groups have
proposed prolyl hydroxylase (PHD) inhibition as a
promising novel strategy in the treatment of inflamma-
tory bowel disease (IBD) [2-4].
To identify the key PHD isoforms (PHD1-3) involved
in the pathogenesis of IBD, we explored their colonic
mucosal expressions in endoscopically derived colonic
mucosal biopsies from healthy controls and patients
with Crohn's disease (CD), ulcerative colitis (UC) and in-
fectious colitis.ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient characteristics
Group Healthy controls UC inflamed UC remission CD inflamed CD remission Infectious colitis
N (Biopsies) 20 16 5 19 10 9
Gender (male/female) 5/15 8/8 4/1 8/11 4/6 6/3
Age, years (mean) 49 38 50 32 49 36
Age, years (range) 12-73 14-58 26-70 11-54 28-73 17-58
Age at diagnosis
A1/A2/A3 1/9/6 0/4/1 4/11/4 0/6/4
Max location of disease
L1/L2/L3/L3 + L4/L4 0/7/9/3/0 3/2/4/0/1
E1/E2/E3 3/10/3 0/4/1
Max disease behaviour
B1/B2/B3 12/3/4 4/3/3
(9P) (4P)
Medication
No 20 5 3 13 8 9
5-aminosalicylates 11 2 6 2
CD: Crohn’s disease; UC: ulcerative colitis; A1: 0-16yrs, A2: 16-40yrs, A3: >40 yrs. Location of disease in and disease behavior of CD was defined as maximal disease
before surgical resection; L1: solely ileal disease, L2: solely colonic disease, L3: ileal and colonic disease, L3 + L4: ileal, colonic and upper gastrointestinal tract
disease, L4: upper gastrointestinal tract disease; B1: non-stricturing, non-penetrating, B2: stricturing, B3: penetrating, (Xp): number of patients when concomitant
perianal disease was present; E1: ulcerative proctitis, E2: left-sided UC, E3: pancolitis.
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Study populations and samples
Colonic mucosal biopsies were taken from endoscopic-
ally inflamed areas of 19 Crohn’s disease (CD) patients
and 10 ulcerative colitis (UC) patients with active dis-
ease, and from completely healed mucosa of 16 CD pa-
tients and 5 UC patients in remission. Samples of 20
healthy controls (HC) and inflamed regions of 9 patients
with infectious colitis were included as controls. Patients
were diagnosed with infectious colitis based on histo-
logical findings (5 out of 9) or positive stool sample cul-
tures (4 out of 9). The patients with infectious colitis
were not known with IBD. Biopsies were stored immedi-
ately after removal in -80°C. IBD patients were either
free of medication use or used 5-aminosalicylates in
monotherapy. This study was approved by the ethical
committee of the University Hospital of Ghent (permitTable 2 Sequences of used qRT-PCR primers and PCR efficien
Gene Symbol Forward Primers (5’-3’)
hSDHA TGGGAACAAGAGGGCATCTG
hPHD1 CCGGAGGAAAAAGCTCGCCACCC
hPHD2 CAGCATGGACGACCTGATAC
hPHD3 AAAGGCGCCCTCCGACTCCT
hIL-8 TGTTCCACTGTGCCTTGGTTTC
hTNF-α ATGAGCACTGAAAGCATGATCC
hCasp3 GAGTGCTCGCAGCTCATACCT
hSDHA, human succinate dehydrogenase complex subunit A; hPHD1, human prolyl
human prolyl hydroxylase domain 3; hIL-8, human interleukin 8; hTNF-α, human tumnumber EC UZG 2004/242) and all participants gave
their written informed consent. Patient characteristics
are summarized in Table 1.
RNA extraction and real-time quantitative PCR
Total RNA was extracted from the colonic mucosal bi-
opsies using the RNeasy Mini Kit (Qiagen, Westburg BV,
Leusden, The Netherlands) and converted to cDNA by
reverse transcription (iScriptTM cDNA synthese kit,
Biorad, CA, USA), according to the manual instructions.
Real-time quantification was performed using Sensi-
MixTM SYBR No-ROX kit (Bioline, Gentaur Europe
BVBA, Kampenhout, Belgium) and 250 nM forward and
reverse primers (BioLegio, Nijmegen, The Netherlands).
A twostep program was run on a LightCycler® 480 II
(Roche, Basel, Switzerland). Cycling conditions were
95°C for 10 minutes, 45 cycles of 95°C for 10 secondscies
Reverse Primers (5’-3’) PCR efficiencies (%)
CCACCACTGCATCAAATTCATG 92
CCTCTGCGGTCCCTAAGGGCTT 105
TACATAACCCGTTCCATTGC 103
CGACCCGTTTCCGGACTGGC 103
TGTGAGGTAAGATGGTGGCTAATAC 102
GAGGGCTGATTAGAGAGAGGTC 112
CCTCACGGCCTGGGATTT 87
hydroxylase domain 1; hPHD2, human prolyl hydroxylase domain 2; hPHD3,
or necrosis factor alpha; hCasp3, human caspase 3.
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Figure 1 mRNA expression of PHD1, PHD2 and PHD3 in human
colonic biopsies. mRNA expression levels of PHD1 (A), PHD2 (B)
and PHD3 (C) in colonic samples of healthy controls, IBD patients
and patients with infectious colitis of the first patient cohort. The
data are expressed as medians and presented on a log scale
(****P < 0.0001, *P < 0.05).
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cate and normalized to the stably-expressed human
succinate dehydrogenase complex subunit (SDHA) levels.
The mRNA expression levels of the inflammatory cyto-
kines interleukin 8 (IL-8) and tumour necrosis factor
alpha (TNF-α) were analyzed as markers of inflammation.
Sequences of the qRT-PCR primers and the PCR efficien-
cies are given in Table 2.Immunohistochemistry
Paraffin-embedded colonic sections of 5 controls, 5 active
UC, 5 active CD and 5 infectious colitis patients were
deparaffinized with xylene, and rehydrated in a graded
series of ethanol. Antigen retrieval was performed by boil-
ing the slides in 10mM sodium citrate buffer with 0.05%
Tween 20 for 20 minutes. Next, endogenous peroxidase
activity was blocked with peroxidase block solution Envi-
sion (Dako) for 15 minutes. Sections were subsequently
blocked with 10% goat serum for 1,5 hours at room
temperature and then incubated overnight with primary
antibodies at 4°C. Primairy antibodies used were rabbit
monoclonal anti-PHD1 (1/50), anti-PHD2 (1/100) and
rabbit polyclonal anti-PHD3 (1/200), obtained from
Abcam. The slides were then treated with HRP labeled
goat anti-rabbit antibody (Envision + System-HRP kit,
Dako) and developed with diaminobenzidine. Counter-
staining was performed with hematoxylin.Western blotting
Human biopsies were lysated, proteins were separated
on 4-12% Bis-Tris SDS-polyacrylamide gels and trans-
ferred to nitrocellulose membranes using iBlot dry blot-
ting (Invitrogen). Afterwards, membranes were blocked
with 5% skimmed milk in TBS-T (50mM Tris (pH 7.6),
150 mM NaCl, 0.1% Tween 20) and incubated overnight
at 4°C in 5% skimmed milk in TBS-T with anti-PHD1
(1/5000, Abcam), anti-PHD2 (1/600, Abcam), anti-PHD3
(1/900, Abcam) and anti-GAPDH (1/2500, Abcam). Bound
antibodies were visualized using the ECL detection kit
BM chemiluminescence Blotting Substrate POD (Roche)
according to manufacturer’s instructions. Quantitative
densitometric analysis using the Image J program was
performed to quantify protein expression levels in each
sample. Data were normalized to the protein expres-
sion of GAPDH.
Table 3 Correlations
PHD1 PHD2 PHD3
IL-8 0.576 (P < 0.001) 0.089 (NS) 0.291 (P = 0.009)
TNF-α 0.706 (P < 0.001) 0.177 (NS) 0.280 (P = 0.012)
Caspase 3 0.594 (P < 0.0001) 0.463 (P = 0.001) 0.262 (NS)
Correlation between the expression of the inflammatory cytokines IL-8 and
TNF-α, the apoptosis marker caspase 3 and the expression of the different
PHD isoforms in colonic mucosal biopsies (Pearsons r for IL-8 and TNF-α,
Spearman’s r for caspase 3).
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The data were statistically analyzed using SPSS Statistics,
version 20, for Windows (SPSS, Chicago, IL). Normality
of the data was checked using the Kolmogorov-Smirnoff
(KS) test. In the case of normally distributed data, the
differences between groups were analyzed using an un-
paired Student’s t-test for independent samples. For
non-normal or unknown data distribution, groups were
compared by using the non-parametric Mann-Whitney
U-test. The KS-test also determined the use of either a
parametric (Pearson) or a non-parametric (Spearman)
correlation test. Two-tailed probabilities were calculated
and p-values less than or equal to 0.05 were considered
statistically significant.
Results
As a first step, we evaluated the expression of the pro-
inflammatory cytokines IL-8 and TNF-alpha to confirm
and define the degree of inflammation in the inflamed
biopsies of IBD patients and patients with infectiousA
B
Figure 2 Protein expression levels of PHD1, 2 and 3 in human colonic
biopsy lysates of 5 healthy controls and 5 UC patients (lane 6, 9 and 10: se
of PHD1, PHD2 and PHD3 in whole biopsy lysates of 5 healthy controls and
moderate CD). The columns represent the densitometric evaluation of thecolitis. It has been previously reported that they are rep-
resentative markers of active inflammation [5,6]. Fur-
thermore, we determined the expression of the apoptosis
marker caspase 3 to be able to evaluate its correlation
with the different PHD isoforms. The inflamed samples
were characterized by highly increased IL-8, TNF-α and
caspase 3 mRNA levels compared to biopsies obtained
from non-inflamed areas and HC (p < 0.0001 for all
groups). IL-8, TNF-α and caspase 3 expression levels in
UC and CD patients in remission were comparable to
those observed in the HC group (data not shown).
Quantitative assessment of PHD1 mRNA levels revealed
a significant increase of PHD1 in inflamed colonic biop-
sies of UC patients (p < 0.0001). This up-regulation was
absent in patients in remission. Expression levels of PHD1
in biopsies from patients with CD and infectious colitis
were only slightly elevated (p < 0.05 and p = 0.063, respect-
ively) compared to HC, despite similarly elevated IL-8
levels (Figure 1A).
For PHD2, no differences were seen in inflamed biop-
sies from patients with UC, CD and infectious colitis
versus non-inflamed biopsies from IBD patients in re-
mission or healthy controls (Figure 1B).
The expression level of the PHD3 gene was signifi-
cantly elevated in samples taken from inflamed colonic
areas in UC patients compared to samples from HC
(p < 0.0001). Inflamed samples from CD patients or in-
fectious colitis nor non-inflamed biopsies from UC pa-
tients in remission showed an up-regulated PHD3
expression (Figure 1C).0
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samples. A) Protein expression of PHD1, PHD2 and PHD3 in whole
vere UC and lane 7 and 8:mild to moderate UC). B) Protein expression
5 CD patients (lane 7 and 8: severe CD and lane 6, 9 and 10: mild to
PHDs, normalized to GAPDH (mean ± SEM)(*P < 0.05).
AC
B
Figure 3 Immunostaining of human biopsies for PHD1, PHD2
and PHD3. A) Immunostaining of PHD1 demonstrates
cytoplasmatic staining of mononuclear cells in the lamina propria
and of regenerative epithelium. B) Immunostaining of PHD2 shows
nuclear staining of epithelium, mononuclear cells in the lamina
propria and smooth muscle cells in the muscularis mucosae. C)
Immunostaining of PHD3 reveals selective staining of the
endothelium of blood vessels. Only the representative images (200x)
of UC patients are given as no disease-dependent localization of the
PHDs was observed.
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and PHD1 expression. In contrast, no correlation was
found between IL-8/TNF-α and PHD2, and only a poor
correlation was observed between IL-8/TNF-α and PHD3.
PHD1 and, to a lesser extent, PHD2 correlated positively
with caspase 3 (p < 0.0001 and p = 0.001, respectively)
(Table 3).
All above reported results were confirmed in a second,
independent patient cohort (data not shown).
Next, the protein expression levels of the three PHD
isoforms were evaluated in biopsies of 5 healthy controls
and in inflamed biopsies of 5 UC patients (3 with severe
disease (Mayo endoscopic score 3), 2 with mild to mod-
erate disease (Mayo endoscopic score 1-2)) and 5 CD
patients (2 with severe disease and 3 with mild to mod-
erate disease). As shown in Figure 2A and Figure 2B,
PHD1 protein expression was significantly increased in
both UC (p < 0.05) and CD (P < 0.05) patients compared
to healthy controls. PHD2 protein levels were not altered
between all groups. The PHD3 protein expression was
not significantly different between inflamed samples of
CD patients versus healthy controls (Figure 2B). How-
ever, the expression in the inflamed samples from se-
verely diseased UC patients (Figure 2A; lane 6, 9 and 10)
was significantly lower compared to healthy controls,.
On immunohistochemistry, no disease-dependant localization
of the PHDs was observed. PHD1 was predominantly
found in regenerative epithelial cells and in the cytoplasm
of mononuclear cells (e.g. dendritic cells, macrophages) in
the lamina propria (Figure 3A). Lymphocytes were PHD1
negative. For PHD2, we observed strong nuclear staining
in a wider range of cell types than for PHD1. Approxi-
mately half of the cells in the epithelium, inflammatory
cell infiltrate (mononuclear cells in the lamina propria and
lymphocytes) and smooth muscle cells in the muscularis
mucosae showed strong PHD2 staining (Figure 3B).
Lastly, we found that the PHD3 protein is specifically
located in the endothelium of blood vessels (Figure 3C).
Discussion
In this study, we analyzed the expression and the localization
of the different PHD isoforms in IBD patients, in order to
identify the primary target(s) for the development of spe-
cific PHD-inhibitors.
The current treatment strategy for both CD and UC is
focused on the suppression of inflammation. Standard
therapy includes corticosteroids, 5-ASA preparations,
immunomodulating drugs and/or biologicals. Despite
these drugs, approximately 70% of the patients with CD
and 35% of patients with UC ultimately come to surgery.
Therefore, research in IBD is still focused on the identi-
fication of novel therapeutics to improve the disease out-
come. In this regard, panhydroxylase inhibitors have
been proposed as promising therapeutic compounds forIBD [1-4], but most of these studies lack human data to
support their claim.
We found strongly increased mRNA expression of
PHD1 and PHD3 in inflamed biopsies from patients
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CD and infectious colitis only displayed a slight increase
in PHD1 expression. Only PHD1 showed a good correl-
ation with the pro-inflammatory markers IL-8 and TNF-α.
Whether or not inflammatory cytokines directly influence
the PHD expression or vice versa is a subject of further
research.
In accordance with our mRNA results, a significant
elevation of PHD1 protein expression was observed in
inflamed biopsies of both UC and CD patients (p < 0.05)
while PHD2 protein levels remained unaltered. PHD3
protein expressions were comparable between all groups
except for UC patients. In contrast to the mRNA levels,
severely diseased UC patients displayed a significant de-
crease in PHD3 expression (p < 0.05). This might, at
least in part, be explained by the fact that Siah 2, a E3
ubiquitine ligase, becomes activated as oxygen concen-
tration decreases due to the extensive consumption of
oxygen by the inflammatory cells, leading to the proteaso-
mal degradation of PHD3 [7,8]. The same phenomenon
was not seen in CD patients, where PHD3 expression did
not follow the severity of the disease. This is not unex-
pected because biopsies from CD patients are always char-
acterized by a discontinuous infiltrate of inflammatory
cells so that the fluctuating levels of high and low oxygen
give rise to a net hypoxic situation that is less pronounced
than in patients with severe UC.
Apart from a role in inflammation, a role of PHDs in
apoptosis has also been suggested. It has been shown
that inhibition of PHD1 and PHD2 results in activation
of HIF-1α and NF-κB [9], both being transcription fac-
tors that regulate the expression of several genes in-
volved in apoptosis [10]. Inflammatory bowel disease is
hallmarked by an increased rate of intestinal epithelial
cell death. In fact, one of the main mechanisms of action
by which panhydroxylase inhibitors are able to suppress
experimental colitis, is probably by reducing colonic epi-
thelial cell apoptosis [11]. Our data also indirectly imply
a role of PHD1 and PHD2 in colonic epithelial apoptosis
as these isoforms show a positive correlation with cas-
pase 3, a marker of apoptosis. It are exactly these iso-
forms that can be found in the colonic epithelium.
In conclusion, only PHD1 was up-regulated both at the
mRNA and the protein level and showed an excellent cor-
relation with both inflammatory markers and apoptosis in
IBD (especially in UC). Allthough we acknowledge that
PHD1 protein expression as such is not directly related to
its enzymatic activity, our exploratory expression analysis
puts PHD1 forward as the primary therapeutic target for
UC and, to a lesser extent, for colonic CD. This is further
supported by the observation that PHD1-deficient mice,
and not PHD2- or PHD3-deficient ones, are highly pro-
tected against colitis by reducing epithelial cell apoptosis
and hence, by maintaining barrier function [12].Abbreviations
PHD: Prolyl hydroxylase domain-containing protein; IBD: Inflammatory bowel
disease; CD: Crohn's disease; UC: Ulcerative colitis.
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